A recent meta-analysis has highlighted the cardiovascular advantages of semaglutide, a diabetes medication also gaining popularity for weight loss. However, concerns over gastrointestinal side effects raise questions about its overall impact on gut health.
Semaglutide, marketed under various brand names such as Ozempic, Wegovy, and Rybelsus, has shown promising results in reducing cardiovascular risk. While only Wegovy has received approval from the Food and Drug Administration (FDA) specifically for weight management in obesity, the other formulations are frequently used off-label for similar purposes.
The analysis revealed a notable reduction in cardiovascular-related complications among semaglutide users. Key findings include:
- A 17% decrease in deaths associated with cardiovascular disease.
- A 76% reduction in hospitalizations due to heart failure.
- A 24% decline in non-fatal myocardial infarction (heart attacks).
- A 24% decrease in the need for coronary revascularization.
- A 35% reduction in stroke incidents among individuals with diabetes.
- A 21% decrease in overall mortality rates.
This meta-analysis, published in the International Journal of Obesity, aims to clarify the specific cardiovascular benefits of semaglutide separate from the weight loss it promotes.
Understanding Dosage and Gastrointestinal Side Effects
Determining how much of semaglutide’s benefits are attributable to the drug itself versus weight loss has been a challenge. The recent study included data from 38 studies, encompassing both diabetic and non-diabetic participants.
Researchers examined the correlation between different dosages of semaglutide and the prevalence of gastrointestinal side effects, which commonly include stomach pain, nausea, constipation, and diarrhea. They found that individuals taking the 2.4 mg dosage experienced the most gastrointestinal issues, and those using the subcutaneous form of semaglutide reported a higher incidence of side effects overall. Notably, there was no significant difference in constipation rates between the subcutaneous and oral versions.
Investigating Cardiovascular Benefits
Dr. André Saad, the lead author of the study and a medical student at the State University of Ponta Grossa in Brazil, emphasized that while weight loss significantly contributes to improved cardiovascular health, it is challenging to separate these effects from those of the medication itself. Dr. Jayne Morgan, a cardiologist not involved in the analysis, acknowledged that the study effectively used statistical modeling to account for variability across the different studies.
Saad noted that semaglutide may have direct cardiovascular benefits, such as stabilizing atherosclerotic plaques and reducing systemic inflammation linked to obesity. Morgan further elaborated that semaglutide positively impacts blood vessels by improving heart blood flow, lowering blood pressure, and reducing liver fat, cholesterol levels, and the decline of kidney function.
Both experts agree that the findings suggest potential cardiovascular benefits for individuals at risk of heart disease, even if they do not have diabetes or obesity.
Oral Semaglutide Shows Lower Mortality Rates
The analysis found that oral semaglutide was more effective than its subcutaneous counterpart in reducing all-cause mortality. Saad speculated that better adherence to treatment and fewer side effects with the oral form might explain this difference. However, he cautioned that results should be interpreted carefully, as there is limited large-scale research on oral semaglutide’s cardiovascular outcomes.
Discontinuation Due to Side Effects
The study highlights that gastrointestinal side effects often lead patients to discontinue semaglutide treatment. Nausea rates rose significantly with higher doses, increasing from 23% in those taking 0.5 mg to 68% in those at the 2.4 mg dosage. Similarly, vomiting rates escalated from 9% to 45% across these dosages. Among subcutaneous users, about 9% to 11% discontinued treatment due to side effects.
With oral semaglutide, the discontinuation rate increased steadily with dosage until reaching 50 mg, where it began to decline. Saad emphasized the importance of ongoing treatment for obesity, comparing it to the management of chronic conditions like diabetes and hypertension.
Managing Gastrointestinal Side Effects
Dr. Mir Ali, a board-certified surgeon and medical director of the MemorialCare Surgical Weight Loss Center, suggested several strategies to mitigate gastrointestinal issues associated with semaglutide. Starting patients on the lowest possible dose and gradually increasing it can help them adjust to side effects. Ali also recommended that patients eat slowly, as semaglutide affects gastric emptying, which can lead to nausea if patients consume meals as they did prior to treatment.
He advised patients to focus on a diet rich in protein and vegetables while reducing carbohydrate intake to minimize gastrointestinal symptoms. In cases of severe nausea, doctors may consider prescribing anti-nausea medications.
As research continues, semaglutide presents significant opportunities for improving heart health and facilitating weight loss, even as the medical community remains vigilant regarding its gastrointestinal side effects.
Related Topic:
Can I Use My HSA For Medical Weight Loss
